Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cortivazol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 18/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortivazol SCHEMBL21340660 | 1.00 | KDM4E (0.82) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL10455984 | 0.99 | KDM4E (0.81) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL6820239 | 0.99 | KDM4E (0.81) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL4969166 | 0.95 | KDM4E (0.74) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL22946293 | 0.94 | KDM4E (0.71) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL11946698 | 0.93 | KDM4E (0.71) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL21340662 | 0.93 | KDM4E (0.70) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL21231563 | 0.92 | KDM4E (0.69) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL29610995 | 0.91 | KDM4E (0.85) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL22946295 | 0.91 | KDM4E (0.67) | KDM4EMEN1KMT2ANPSR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8703 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522805-B2 | Method for obtaining cell spheroids | D.I.V.A EXPERTISE (FR) | 2026-01-13 | — | — | US | claimed |
| US-12512224-B2 | Method of discovering disease-relevant microbial consortia using machine-learning model | IMMUNOBIOME INC. (KR) | 2025-12-30 | — | — | US | claimed |
| EP-4301343-B1 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME | TLC BIOPHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-20250222117-A1 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | PURDUE RESEARCH FOUNDATION | 2025-07-10 | — | — | US | claimed |
| US-20250205227-A1 | METHODS FOR ADMINISTERING CORTICOSTEROIDS | SPARROW PHARMACEUTICALS, INC. | 2025-06-26 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-05-08 | — | — | US | claimed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | claimed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| WO-1992008730-A1 | NOVEL STEROIDAL ORGANIC SUBSTANCE CRYSTALLIZATION METHOD AND COMPOUNDS THEREBY OBTAINED | LABORATOIRE THERAMEX S.A. (MC) | 1992-05-29 | — | — | WO | claimed |
| US-5049389-A | Non-phospholipd lipid, delivery by inhalation | LIPOSOME TECHNOLOGY, INC. (US) | 1991-09-17 | — | — | US | claimed |
| US-5043165-A | Cholesterol and salt; antiallergens, antiinflammatory agents, skin disorders | LIPOSOME TECHNOLOGY, INC. (US) | 1991-08-27 | — | — | US | claimed |
| US-4970206-A | TRANSDERMAL DRUG DELIVERY | MERCK & CO., INC. (US) | 1990-11-13 | — | — | US | claimed |
| WO-1990006775-A1 | A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS | LIPOSOME TECHNOLOGY, INC. (US) | 1990-06-28 | — | — | WO | claimed |
| US-4906476-A | Novel liposome composition for sustained release of steroidal drugs in lungs | LIPOSOME TECHNOLOGY, INC. | 1990-03-06 | — | — | US | claimed |
| CN-2041434-U | FULLY INTEGRATED AUTOMATIC TIME CONTROLLER | YANG PEIXIN (CN) | 1989-07-19 | — | — | CN | claimed |
| EP-0298133-A1 | APPARATUS FOR THE PREVENTION OF DISASTERS | NOHMI BOSAI LTD. (JP) | 1989-01-11 | — | — | EP | claimed |
| EP-0173478-A1 | Treatment of skin disorders | SCOTIA HOLDINGS PLC (GB) | 1986-03-05 | — | — | EP | claimed |